NANOMEDICINE RESEARCH CORE (NRC)
纳米医学研究核心 (NRC)
基本信息
- 批准号:8166145
- 负责人:
- 金额:$ 30.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-06-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAreaBasic ScienceBiological ProductsChronic Fatigue SyndromeClinicalCollaborationsCommunitiesComputer Retrieval of Information on Scientific Projects DatabaseDegenerative DisorderDiseaseDrug Delivery SystemsDrug FormulationsDrug KineticsEquipmentEvaluationFloridaFundingFutureGoalsGrantGrowthHistorically Black Colleges and UniversitiesHuman ResourcesImageInstitutionMalignant NeoplasmsMinorityMissionOutcomePharmacologic SubstancePharmacy (field)Pharmacy facilityResearchResearch ActivityResearch InfrastructureResearch PersonnelResourcesScientistSeriesSourceStrokeTechnologyTrainingTranslatingUnited States National Institutes of HealthUniversitiesabstractingbench to bedsidecollegeinnovationnanomedicinenanoparticleprogramsreceptor
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
ABSTRACT:
Nanomedicine Research Activity (NRA) is an extended outcome of the previously funded Drug Delivery Activity by the RCMI program. The last several years have seen significant growth in the drug delivery and pharmaceutics area at the College of Pharmacy, FAMU. The objective and mission of the drug delivery activity has been to give the scientific community at FAMU the requisite support to excel in targeted drug delivery. Currently, we have established basic infrastructure in the area of drug delivery and the future direction of this activity is to develop expertise in the emerging area of Nanomedicine by focusing specifically in the area of nanoparticles. The Long-term goal of this activity is to establish resources and expertise in the area of nanoparticle technology which could be applied to imaging of various degenerative diseases like Alzheimer and stroke and also to target various receptors in disease states like cancer and chronic fatigue syndrome. The specific aims of this activity are: Specific Aim 1: Establish suitable infrastructure for nanoparticle drug delivery research by hiring key personnel and equipment. Specific Aim 2: To develop collaborations between research investigators with basic science and clinical backgrounds to develop innovative drug delivery technologies which can be translated from bench to bedside. Specific Aim 3: To develop resources and expertise for biopharmaceutical and pharmacokinetic evaluation of drugs and formulations. Specific Aim 4: Provide opportunities for the training of minority scientists in the area of nanoparticle formulation and delivery. These capabilities will strengthen the infrastructure and enable the investigators at historically black institutions like Florida A&M University to be able to attract extra-mural funding like R-series grants.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mandip Singh Sachdeva其他文献
Mandip Singh Sachdeva的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mandip Singh Sachdeva', 18)}}的其他基金
Exosomal Based micro RNA delivery for Resistant Lung Cancer
基于外泌体的 micro RNA 递送治疗耐药性肺癌
- 批准号:
10629892 - 财政年份:2023
- 资助金额:
$ 30.45万 - 项目类别:
Role of Telmisartan on Intra-Tumoral Distribution of Targeted Nanoparticles
替米沙坦对靶向纳米颗粒肿瘤内分布的作用
- 批准号:
8791884 - 财政年份:2014
- 资助金额:
$ 30.45万 - 项目类别:
Role of Telmisartan on Intra-Tumoral Distribution of Targeted Nanoparticles
替米沙坦对靶向纳米颗粒肿瘤内分布的作用
- 批准号:
8637758 - 财政年份:2014
- 资助金额:
$ 30.45万 - 项目类别:
Targeted Nanocarrier Combination Based Therapy for Lung Cancer
靶向纳米载体组合治疗肺癌
- 批准号:
8552025 - 财政年份:2013
- 资助金额:
$ 30.45万 - 项目类别:
Targeted Nanocarrier Combination Based Therapy for Lung Cancer
靶向纳米载体组合治疗肺癌
- 批准号:
8355084 - 财政年份:2012
- 资助金额:
$ 30.45万 - 项目类别:
Targeted Nanocarriers for Treatment of Lung Cancer
用于治疗肺癌的靶向纳米载体
- 批准号:
8018928 - 财政年份:2011
- 资助金额:
$ 30.45万 - 项目类别:
Targeted Nanocarriers for Treatment of Lung Cancer
用于治疗肺癌的靶向纳米载体
- 批准号:
8537387 - 财政年份:2011
- 资助金额:
$ 30.45万 - 项目类别:
Targeted Nanocarriers for Treatment of Lung Cancer
用于治疗肺癌的靶向纳米载体
- 批准号:
8321434 - 财政年份:2011
- 资助金额:
$ 30.45万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 30.45万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 30.45万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 30.45万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 30.45万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 30.45万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 30.45万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 30.45万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 30.45万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 30.45万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 30.45万 - 项目类别: